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(patient severity), biochemical parameters (lipids, glucose, etc.)
and cost model. The general morbidity charge was quantiﬁed
beginning from Adjusted Clinical Groups (http://www.acg.
jhph.edu). The program provides the utilization bands of
resources (RUB, co-morbidities levels). It was considered ﬁxed/
semi-ﬁxed cost structure/salary/services) and variable one
(diagnostics/therapeutical requests, referrals, drugs). Logistical
regression analysis was effected (procedure: enter) and the cova-
riance (ANCOVA) for the correction of the models (procedure:
Bonferroni), according to the recommendations of Thompson-
Barber. Program SPSSWIN; p < 0.05. RESULTS: A total of
35,207 subjects 44 years were studied, 10.9% (95% CI: 13.3–
15.1%) show osteoporosis (average aged: 62.5  11.8 years;
woman: 94.4%). The patients with osteoporosis presented main
general morbidity (RUB: 2.9  0.6 vs. 2.7  0.7; episodes:
8.0  4.5 vs. 5.7  3.7), total cholesterol (213.2  36.1 vs.
208.9  30.9 mg/ml), visits (12.9  10.9 vs. 9.6  9.3) and
polypharmacy (41.2% vs. 22.2%), p < 0.001. The osteoporosis
had an independent association in presence from fracture
(OR = 1.4), ﬁbromyalgia (OR = 1.3), dyslipidemia (OR = 1.3),
asthma (OR = 1.2), depression (OR = 1.2) y thyroid diseases
(OR = 1.2), p < 0.001. The average unitary/total cost adjusted
for year, gender and RUB was €1387.28 vs. €808.98; and the
pharmaceutical of €1018.62 vs. €522.33; p < 0.001. All compo-
nents of outpatient management costs were signiﬁcantly higher in
the osteoporosis group. Eighteen percent of the total cost was
related to drugs. CONCLUSIONS: Patients with osteoporosis
presented a high morbidity (general) and speciﬁc one, existing
differences of gender (women), producing a high consume of
sanitary recourses.
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OBJECTIVES: 1) To assess the willingness of patients to
provide information about medical treatment, and 2) to prac-
tically demonstrate that useful information can be collected
METHODS: Public acceptability towards reporting side-effects
and efﬁcacy of medical treatments was assessed by 1) online
questionnaire, and 2) assisted questionnaire. Results from the
ﬁrst 137 respondents to the on-line questionnaire and 115
respondents to the assisted questionnaire are reported. A total
of 110 leaﬂets were distributed inviting patients to log on to a
dedicated website and provide information on post-vaccination
symptoms. Information was gathered on the day of vaccina-
tion, two days later and at day eight. RESULTS: A total of
94% of interviewees were aware of the possibility of side
effects. Of interviewees who had personal experience of side
effects, 39% did not report them. The perceived principle
conduit (81%) for reporting was to the physician. The moti-
vating factors for reporting adverse drug reactions (ADR’s) in
order of frequency was stated to be, ensuring medical safety of
others (31%), ensuring their own future good health (28%) the
advice of pharmacists/nurses (12%) and ﬁnancial incentives if
available (7%). A total of 73% reported willingness to report
side-effects via the Internet. A total of 110 leaﬂets were distrib-
uted at an inﬂuenza vaccine clinic inviting patients to log on to
an interactive website and provide information. 73 (66%) reg-
istered on the day of vaccination, 70 (96%) responded at day
two and 66 (90%) at day eight. Statistics on pain and discom-
fort demonstrate that while the majority of patients have no
pain, 8% experienced signiﬁcant discomfort and 3% pain for
greater than one hour. Of side effects reported, none required
medical attention and the majority were self-limiting. CON-
CLUSIONS: We have conﬁrmed that patients are willing to
provide information about medical treatment via an interactive
web-based system. This technique has potential for the conduct
of naturalistic studies and for post-marketing surveillance.
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OBJECTIVES: When conducting systematic reviews of ran-
domised controlled trials (RCTs), an important step is to criti-
cally assess the quality of included studies. As emphasis on sound
trial design has increased over the years, we sought to establish
how quality of studies included in systematic reviews is associ-
ated with the publication year of those studies. METHODS: We
analysed the studies included in 4 large, clinical systematic
reviews of randomised controlled trials conducted by Heron in
the last 6 months. These covered 4 disease areas: oncology,
hyperlipidaemia, anaesthesia, and serious bacterial infection. The
data extracted included a critical appraisal of study quality based
on means of quality scales. These were the Jadad scale, which
assesses randomisation, blinding, patient attrition and reporting
quality and gives a score from 1 (low) to 5 (high), and the
allocation concealment grade, which assess whether allocation to
treatment was adequately concealed. We analysed trends in both
Jadad score and allocation concealment grade by year of publi-
cation, with stratiﬁcation by disease area. RESULTS: A total of
291 trials were included in the analyses from the 4 reviews. Most
of these were carried out between 1981–2008. The average
overall Jadad score was 2.3, suggesting low overall trial quality.
Jadad score increased from a mean of 1.4 over the period 1981–
1986 to 2.9 over the period 2001–2006. Furthermore there was
an increase in the percentage of high quality (Jadad score 4–5)
trials—from 6% in 1981–1986 to 36% in 2001–2006. Only 3%
of RCTs from the period 1981–1990 recorded adequate alloca-
tion concealment; this increased to 26% over the period 1996–
2006. CONCLUSIONS: There was an observable increase in
trial quality over the period analysed. However, the mean Jadad
score, and the proportion of trials with adequate concealment of
allocation remained low, even by 2006, indicating the need for
continued attention to study quality.
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Shannon PR, Beard S
RTI Health Solutions, Manchester, UK
OBJECTIVES: Although effective post-approval communication
is vital in building awareness in the clinical community of newly
approved and recommended drugs, the development of such
communications can often have a lower priority than supporting
a drug through its formal regulatory submission. In this study we
considered how standard Excel-based cost effectiveness models
could be adapted to enhance communication of economic value.
METHODS: Even with a clear and positive regulatory approval
and recommendation, from groups such as National Institute for
Health and Clinical Excellence (NICE), an additional hurdle is
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often seen in effectively communicating this to treatment prac-
tices within the clinical community to the Primary Care Trust
(PCT) level. Such delays can result in the continued prescribing of
less cost-effective drugs. We, therefore, looked at several poten-
tial approaches to enhance communications through improved
user interface capabilities of existing Excel-based models. Three
approaches were considered, all utilising existing Windows-
based tools and programming languages: HTML, Visual Basic,
or HTML/Visual Basic (hybrid). RESULTS: We successfully
developed a two-step methodology, based on a HTML/
VisualBasic approach, which can be used to quickly develop
sophisticated graphical user interfaces directly within the struc-
ture of an existing economic model. The advantage of this novel
approach is that there is no longer a need to rely on full replica-
tions of models in a separate programming language (such as
shockwave), which carries consistency issues, or the limited basic
spreadsheet interface. Also, the approach can be applied itera-
tively during model design for submission to a regulatory body,
which is a more efﬁcient development process. CONCLUSIONS:
A new method of presenting pharmacoeconomic results has been
developed, which can be designed within existing Excel-based
economic models, providing an enhanced, user-friendly, interac-
tive tool which can replicate real-world prescribing patterns for a
given scenario. These tools can greatly improve communications
of economic and clinical messages to PCTs.
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OBJECTIVES: To determine whether the Social Security Institu-
tion of Turkey has an appropriate system to collect and process
data in order to conduct budget impact analysis. METHODS:
A literature review was conducted in order to specify the data
needed for budget impact studies. Then, interviews with the
personnel of the Monitoring and Evaluation Department and
Pharmaceuticals and Pharmacy Department in the Social Security
Institution were made. Besides, the literature concerning General
Health Insurance MEDULA system was reviewed. Data was
assessed in terms of its existence and accessibility. RESULTS:
After using Web Electronic Bill System (w-ELF) in 2006,
MEDULA was established in order to transfer data between
health care settings and general health insurance system in 2007
in Turkey. Currently, patient characteristics such as age and
gender, information regarding diagnosis, examination, consulta-
tion, analysis, operation, complications and pharmaceuticals and
medical supplies used can be recorded via MEDULA. However,
patients and number of patients who have a speciﬁc health con-
dition or who use a certain pharmaceutical product cannot be
determined via web services of the system. Similarly, costs paid
for a speciﬁc medical treatment cannot be identiﬁed via
MEDULA. On the other hand, it is indicated that there is a
project to determine number of patients who have a speciﬁc
health condition through the system. CONCLUSIONS:
Although there is relevant raw data, number of eligible people
with a speciﬁc indication, extent of implementation of a phar-
maceutical and incremental cost per patient which are necessary
for budget impact studies cannot be accessed through the existent
system in the Social Security Institution of Turkey. Thus, some
improvement in data processing is needed.
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COST-UTILITY ANALYSIS BY DIAGNOSIS
Bush S
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OBJECTIVES: To determine a rule or the threshold beyond
which missing data affects utility estimates, thus requiring resort
to imputation techniques. This analysis examined UK data and is
based on patient and payers’ perspectives. This paper moves
beyond the now established consensus against listwise and pair-
wise deletion of missing data toward comparably simple methods
of analysis that achieve greater accuracy. METHODS: EuroQoL
EQ-5D measurements of health utility obtained by survey of
secondary care patients after hospitalisation were examined in
order to develop missing data thresholds beyond which overall
data quality would be compromised and thus imputation tech-
niques required. Using gender, index age, length of stay in hos-
pital, number of comorbidities, and cost of care, patients were
stratiﬁed according to a primary diagnoses of 5 major chronic
conditions, in terms of cost. Each dataset, consisting of between
150 and 450 patients, was randomly assigned missing values,
based on two broad classes of randomness in the literature:
missing at random data and not missing at random data. Not
missing at random data was deﬁned as data containing paired
variables with correlation coefﬁcients of great than 0.50. Com-
parisons among primary ICD-10 diagnoses set at 5%, 10%,
15%, and 20% were examined. The missing data threshold for
each diagnosis was then calculated by model simulation using
various degrees of missing data. RESULTS: For cardiovascular
diseases, the missing data threshold was between 8.5% and 12%.
Rates of missingness beyond these levels tended to decrease the
accuracy of utility measures when compared with the full base-
line dataset. For diabetes, chronic pulmonary disease, and mus-
cular skeletal disorders, the range was lower. Therefore, for a
given cost of care, cost-utility ratios decline due to the increase in
uncertainty of the estimates. CONCLUSIONS: Descriptive mea-
sures of health status are affected by diagnosis and other factors.
The development of a rule that enables researchers to determine
whether missing data is likely to have a material effect on the
measurement of health status can lead to improved research
quality and, in turn, better allocation of health care resources.
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SOCIAL DISCOUNTING INTHE ECONOMIC EVALUATION OF
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Valentim J1, Prado Jr JM2
1University of São Paulo, São Paulo, SP, Brazil, 2IMT Lucca Institute for
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OBJECTIVES: To provide a ready-to-use framework for com-
puting the social discount rate, the proper rate for discounting of
social programmes, including health care programmes, given the
inoptimality of market mechanisms to derive the optimal dis-
count rate. METHODS: A social time preference methodology
derived from Feldstein work (“The derivation of social time
preference rates”, Kyklos 18, 1965) is applied to calculate social
discount rates as social time preference (STP) rates across 167
countries for a speciﬁc year (2006) and across time from 2005–
2050 for a country case (Brazil). STR rate derived is deﬁned as
dt = (1 + pt)1-a(1 + gt)s(1 + r) - 1, where a is the population
weight, p the population growth, g the per-capita income growth,
s the coeffcient of risk aversion and r the pure time preference
rate. Data were obtained in the literature and databases (World
Development Indicators (World Bank, 2007), World Economic
Outlook (IMF, 2007) and IBGE (Instituto Brasileiro de Geograﬁa
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